International Assets Investment Management, LLC Bei Gene, Ltd. Transaction History

International Assets Investment Management, LLC

$1.2 Trillion
Q4 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2021 Jul 14, 2021	SELL	$292.75 - $367.01 $4,976 - $6,239	-17 Closed	0 $0
Q4 2020 Jan 22, 2021	BUY	$221.31 - $316.61 $3,762 - $5,382	17 New	17 $4.39 Million

Others Institutions Holding BGNE

# of Institutions

252

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

Baker Bros. Advisors LP New York, NY

10.6M
Shares

$1.91 Billion
25.41% of portfolio
Capital International Investors Los Angeles, CA

6.43M
Shares

$1.16 Billion
0.29% of portfolio
Hhlr Advisors, Ltd. Grand Cayman, E9

5.18M
Shares

$935 Million
26.65% of portfolio
Primecap Management CO Pasadena, CA

4.97M
Shares

$899 Million
0.84% of portfolio
Baillie Gifford & CO

3.71M
Shares

$669 Million
0.64% of portfolio

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of International Assets Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on International Assets Investment Management, LLC with notifications on news.

Account